The effect of risk factors on surgical and oncological results in high-risk prostate cancer: A multicentre study of the urooncology society, Turkey

被引:1
|
作者
Izol, Volkan [1 ]
Akdogan, Nebil [1 ]
Ozen, Haluk [2 ]
Akdogan, Bulent [2 ]
Kural, Ali Riza [3 ]
Tuna, Mustafa Bilal [3 ]
Sozen, Sinan [4 ]
Turkeri, Levent [5 ]
Tansug, Mustafa Zuhtu [1 ]
机构
[1] Cukurova Univ, Fac Med, Dept Urol, TR-01330 Adana, Turkey
[2] Hacettepe Univ, Fac Med, Dept Urol, Ankara, Turkey
[3] Acibadem Univ, Acibadem Maslak Hosp, Dept Urol, Istanbul, Turkey
[4] Gazi Univ, Fac Med, Dept Urol, Ankara, Turkey
[5] Acibadem Univ, Altunizade Hosp, Dept Urol, Istanbul, Turkey
关键词
RADICAL PROSTATECTOMY; SURVIVAL; MORTALITY; THERAPY; OUTCOMES; IMPACT; MEN;
D O I
10.1111/ijcp.14281
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose To evaluate the effect of risk factors and selected surgical methods on operative and oncological results of patients undergoing radical prostatectomy (RP) with high-risk prostate cancer (HRPC). Methods Retrospective analysis of patients who underwent RP for HRPC from 13 urology centres between 1990 and 2019 was performed. Groups were created according to the risk factors of D'Amico classification. Patients with one risk factor were included in group 1 where group 2 consisted of patients with two or three risk factors. Results A total of 1519 patients were included in this study and 1073 (70.6%) patients were assigned to group 1 and 446 (29.4%) patients to group 2. Overall (biochemical and/or clinical and/or radiological) progression rate was 12.4% in group 1 and 26.5% in group 2 (P = .001). Surgical procedure was open RP in 844 (55.6%) patients and minimally invasive RP in 675 (44.4%) patients (laparoscopic and robot-assisted RP in 230 (15.1%) and 445 (29.3%) patients, respectively). Progression rates were similar in different types of operations (P = .22). Progression rate was not significantly different in patients who either underwent pelvic lymph node dissection (PLND) or not in each respective group. Conclusion RP alone is an effective treatment in the majority of patients with HRPC and PLND did not affect the progression rates after RP. According to the number of pre-operative high-risk features, as the number of risk factors increases, there is a need for additional treatment.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Genomics and risk stratification in high-risk prostate cancer
    Al Awamlh, Bashir Al Hussein
    Shoag, Jonathan E.
    NATURE REVIEWS UROLOGY, 2019, 16 (11) : 641 - 642
  • [22] Surgical Outcomes in High-risk Prostate Cancer and Salvage Radical Prostatectomy
    Avda, Yuval
    Modai, Jonathan
    Shpunt, Igal
    Dinerman, Michael
    Shilo, Yaniv
    Croock, Roy
    Jaber, Morad
    Linder, Uri
    Leibovici, Dan
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (12): : 777 - 782
  • [23] Genomics and risk stratification in high-risk prostate cancer
    Bashir Al Hussein Al Awamlh
    Jonathan E. Shoag
    Nature Reviews Urology, 2019, 16 : 641 - 642
  • [24] Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer
    Andrew M. Fang
    Jamaal Jackson
    Justin R. Gregg
    Lisly Chery
    Chad Tang
    Devaki Shilpa Surasi
    Bilal A. Siddiqui
    Soroush Rais-Bahrami
    Tharakeswara Bathala
    Brian F. Chapin
    Current Treatment Options in Oncology, 2024, 25 : 66 - 83
  • [25] Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer
    Fang, Andrew M.
    Jackson, Jamaal
    Gregg, Justin R.
    Chery, Lisly
    Tang, Chad
    Surasi, Devaki Shilpa
    Siddiqui, Bilal A.
    Soroush-Rais-Bahrami
    Bathala, Tharakeswara
    Chapin, Brian F.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (01) : 66 - 83
  • [26] Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer
    Fang, Andrew M.
    Jackson, Jamaal
    Gregg, Justin R.
    Chery, Lisly
    Tang, Chad
    Surasi, Devaki Shilpa
    Siddiqui, Bilal A.
    Rais-Bahrami, Soroush
    Bathala, Tharakeswara
    Chapin, Brian F.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (05) : 617 - 618
  • [27] Neoadjuvant therapies for surgical management of high-risk, localized prostate cancer
    Mikkilineni, Nina
    Hyams, Elias S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S662 - S675
  • [28] New surgical approaches for clinically high-risk or metastatic prostate cancer
    Dell'Oglio, Paolo
    Stabile, Armando
    Gandaglia, Giorgio
    Zaffuto, Emanuele
    Fossati, Nicola
    Bandini, Marco
    Suardi, Nazareno
    Karakiewicz, Pierre I.
    Shariat, Shahrokh F.
    Montorsi, Francesco
    Briganti, Alberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (11) : 1013 - 1031
  • [29] Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: Results of a prospective study.
    Zhuang, Junlong
    Zhang, Shun
    Qiu, Xuefeng
    Zhou, Feng
    Guo, Hongqian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 327 - 327
  • [30] Defining high-risk prostate cancer
    Goldberg, Hanan
    Baniel, Jack
    Yossepowitch, Ofer
    CURRENT OPINION IN UROLOGY, 2013, 23 (04) : 337 - 341